Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides

1. A method of treating a subject afflicted with hypertriglyceridemia, comprising administering to the subject a gamma-secretase inhibitor in an amount effective to treat the hypertriglyceridemia in the subject.

2. The method of claim 1 , wherein the administration reduces the subject's serum triglyceride level.

3. The method of claim 2 , wherein the administration reduces the triglyceride level in the subject's very low-density lipoprotein (VLDL) serum fraction.

4. The method of claim 2 , wherein the administration reduces the subject's serum triglyceride level and serum apolipoprotein C3(ApoC3) level.

5. The method of claim 1 , wherein administration of the gamma-secretase inhibitor inhibits whole-body gamma-secretase.

6. The method of claim 1 , wherein administration of the gamma-secretase inhibitor inhibits liver gamma-secretase more than inhibiting gamma-secretase elsewhere in the subject.

7. The method of claim 1 , wherein the administration of the gamma-secretase inhibitor targets the gamma-secretase inhibitor to the liver.

8. The method of claim 1 , wherein the administration of the gamma-secretase inhibitor targets the gamma-secretase inhibitor to hepatocytes.

9. The method of claim 6 , wherein the gamma-secretase inhibitor is (i) coupled to a ligand molecule targeted to a receptor on a hepatic cell, or (ii) administered by a bio-nanocapsule.

10. The method of claim 6 , wherein gastrointestinal Notch activity is substantially uninhibited.

11. The method of claim 1 , wherein the gamma-secretase inhibitor is a small molecule inhibitor, an oligonucleotide capable of hybridizing to an RNA encoding a subunit of gamma secretase in a cell, or an adenoviral vector capable of expressing the oligonucleotide.

12. The method of claim 11 , wherein the gamma-secretase inhibitor is an oligonucleotide.

13. The method of claim 12 , wherein the oligonucleotide is an antisense oligonucleotide, an RNA-interference inducing compound, or a ribozyme.

14. The method of claim 12 , wherein the oligonucleotide is targeted to hepatocytes.

15. The method of claim 12 , wherein the oligonucleotide comprises 1, 2, 3, 4, or 5 or more stretches of nucleotides in a sequence that is complementary to nicastrin-encoding mRNA, presenilin 1-encoding mRNA and presenilin 2-encoding mRNA, or APH1A-encoding mRNA and APH1B-encoding mRNA, wherein each stretch of complementary continguous nucleotides is at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more nucleotides in length.

16. The method of claim 12 , wherein the oligonucleotide is modified to increase its stability in vivo.

17. The method of claim 11 , wherein the gamma-secretase inhibitor is a small molecule inhibitor.

18. The method of claim 17 , wherein the small molecule inhibitor is 2,2-dimethyl-N—((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentafluoro-propyl)-malonamide, (S)-2-((S)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide, bis(fluoroalkyl)-1,4-benzodiazepinone, (2S)-2-hydroxy-3-methyl-N-((1S)-1-methyl-2-{[(1S)-3-methyl-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-2-oxoethyl)butanamide, cis-3-[4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl] propanoic acid, N-[N-(3,5-difluorophenacetyl)-1-alanyl]-S-phenyglycine t-butyl ester, bis(fluoroalkyl)-1,4-benzodiazepinone, or N-[(1S)-2-[[(7S)-6,7-dihydro-5-methyl-6-oxo-5H-dibenz[b,d]azepin-7-yl]amino]-1-methyl-2-oxoethyl]-3,5-difluoro-benzeneacetamide.

19. A method of reducing a subject's plasma glucose level, comprising administering to a subject in need thereof a gamma-secretase inhibitor in an amount effective to reduce the subject's glucose level.